title: Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.
abstract: Interleukin 6 and C-reactive protein (CRP) were determined prior to IL-2 therapy in sera from metastatic melanoma patients. Patients with elevated serum IL-6 (> 20 pg ml-1) and/or CRP (> 10 mg l-1) levels were associated with resistance to IL-2 therapy. A correlation between high serum IL-6 levels and a shorter median survival was also observed.
authors.affiliation: Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Tartour
authors.forename: T
authors.initials: T
authors.lastname: Dorval
authors.forename: V
authors.initials: V
authors.lastname: Mosseri
authors.forename: L
authors.initials: L
authors.lastname: Deneux
authors.forename: C
authors.initials: C
authors.lastname: Mathiot
authors.forename: H
authors.initials: H
authors.lastname: Brailly
authors.forename: F
authors.initials: F
authors.lastname: Montero
authors.forename: I
authors.initials: I
authors.lastname: Joyeux
authors.forename: P
authors.initials: P
authors.lastname: Pouillart
authors.forename: W H
authors.initials: WH
authors.lastname: Fridman
mesh_terms: D000328:Adult; D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008545:Melanoma / Q000097:blood* / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D011379:Prognosis
chemical_list: D007376:Interleukin-2; D015850:Interleukin-6; D002097:C-Reactive Protein